Heron Therapeutics announced the appointment of Craig Collard as CEO, effective April 3. Collard succeeds Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board. In addition, as part of the leadership change, the Board elected Adam Morgan as Chairman. Collard brings more than three decades of experience leading innovative pharmaceutical companies through periods of strategic change to deliver growth and enhanced value for stockholders. Most recently, as CEO of Veloxis Pharmaceutics A/S before its acquisition by Asahi Kasei Corp.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRTX:
- Heron Therapeutics Dives on Zynrelef Troubles
- Heron Therapeutics price target lowered to $10 from $15 at Evercore ISI
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics reports Q4 EPS (17c), consensus (28c)
- Heron announces CMS granted pass-through payment status for APONVIE
